The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 7890-7897
DOI: 10.1007/s00259-026-08136-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 15.08.2026. Verfasst von Abdallah Nour Ali und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. a.n.a.ali@…. Hauptthemen laut MEDLINE: Dopamine Plasma Membrane Transport Proteins, Parkinson Disease, Tomography, Emission-Computed, Single-Photon, Tropanes. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Several centrally acting medications may interfere with dopamine transporter (DAT) imaging using [¹²³I]I-FP-CIT SPECT, potentially leading to misinterpretation. We therefore evaluated the effects of several medications on striatal DAT binding assessed by [ 123 I]I-FP-CIT SPECT in patients with Parkinson’s disease (PD).
Methods
Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI). PD patients with abnormal [¹²³I]I-FP-CIT SPECT scans, and available medication and clinical data, were included. The effects of bupropion, venlafaxine, methylphenidate, modafinil, and codeine were assessed. Striatal specific binding ratios (SBRs) of the caudate nucleus and putamen were analysed using multivariable linear regression models adjusted for relevant covariates.
Results
Data from 752 PD patients were included. Use of the evaluated medications was associated with lower SBRs in the ipsilateral and contralateral caudate nucleus (-13.5% and -13.7%, respectively) and putamen (-6.5% and -8.2%, respectively; all p < 0.01). Medication-specific analyses showed the largest reductions for methylphenidate and modafinil, with relative reductions in caudate nucleus SBRs of up to -33.2% and -25.5%, respectively (both p < 0.01). In contrast, bupropion and venlafaxine were associated with smaller, but still significant, reductions, whereas no significant associations were observed for codeine.
Conclusion
Use of methylphenidate and modafinil in particular is associated with significantly reduced striatal [¹²³I]I-FP-CIT binding in PD patients. Medication use should be carefully considered when interpreting DAT SPECT scans. Temporary discontinuation may be considered in selected cases when clinically appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. a.n.a.ali@amsterdamumc.nl.
- Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
- Department of Pharmacy, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Zitieren
APA
Ali, A. N., Malik, I., Booij, J., & Chahid, Y. (2026). The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 7890-7897. https://doi.org/10.1007/s00259-026-08136-2
Vancouver
Ali AN, Malik I, Booij J, Chahid Y. The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):7890-7897. doi:10.1007/s00259-026-08136-2
BibTeX
@article{Ali2026,
author = {Ali, Abdallah Nour and Malik, Ilham and Booij, Jan and Chahid, Youssef},
title = {The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {7890--7897},
doi = {10.1007/s00259-026-08136-2}
}
EUVIMED